Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2021; 27(22): 3073-3084
Published online Jun 14, 2021. doi: 10.3748/wjg.v27.i22.3073
Published online Jun 14, 2021. doi: 10.3748/wjg.v27.i22.3073
Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease
Jie Zhou, Yi-Ling Wang, Yue Zhao, Jin-Yi Lang, Shun Lu, Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu 610041, Sichuan Province, China
Yang Yang, Department of Oncology, The Third People's Hospital of Chengdu, Chengdu 255415, Sichuan Province, China
Wen-Jing Ye, Si-Yao Deng, Department of School of Medicine, University of Electronic Science and Technology of China, Chengdu 397992, Sichuan Province, China
Jin-Yi Lang, Shun Lu, Department of Radiological Protection, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu 229717, Sichuan Province, China
Author contributions: Zhou J and Yang Y performed the majority of experiments and analyzed the data; Wang YL and Zhao Y performed the molecular investigations; Ye WJ and Deng SY designed and coordinated the research; Lang JY and Lu S wrote the paper; Zhou J and Yang Y contributed equally to this work.
Supported by National Natural Science Foundation of China , No. 81900498 .
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Sichuan Cancer Hospital.
Institutional animal care and use committee statement: All experimental procedures with mice were performed in accordance and compliance with the regulations of the Laboratory Animal Welfare and Ethics Committee of Sichuan Cancer Hospital & Institute.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shun Lu, MD, Chief Physician, Department of Radiation Oncology, Sichuan Cancer Hospital, No. 55 Renmin South Road, Chengdu 610041, Sichuan Province, China. lushousi90036@163.com
Received: March 7, 2021
Peer-review started: March 7, 2021
First decision: March 27, 2021
Revised: April 9, 2021
Accepted: April 28, 2021
Article in press: April 28, 2021
Published online: June 14, 2021
Peer-review started: March 7, 2021
First decision: March 27, 2021
Revised: April 9, 2021
Accepted: April 28, 2021
Article in press: April 28, 2021
Published online: June 14, 2021
Core Tip
Core Tip: In this study, we discovered that enhancer of zeste homolog 2 contributed to apoptosis and inflammatory response by inactivating janus kinase 2/signal transducer and activator of transcription signaling in inflammatory bowel disease (IBD). Enhancer of zeste homolog 2 may be applied as a potential target for IBD therapy.